Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Airlines Group Inc (AAL) vs Heron Therapeutics Inc (HRTX) Price & Performance

American Airlines Group Inc
Heron Therapeutics Inc

Price performance

Price movement over the last 24 hours

Key statistics

American Airlines Group Inc vs Heron Therapeutics Inc — how do they compare? American Airlines Group Inc trades at $16.58 (market cap $11.38B), while Heron Therapeutics Inc trades at $0.43 (market cap $80.58M). The key difference: American Airlines Group Inc is far larger — about 141.2× Heron Therapeutics Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

AALHRTX
Market Cap
$11.38B$80.58M
Sector
IndustrialsHealth
52-Week High
$18.15$2.23
52-Week Low
$10.18$0.39
Enterprise Value
$38.97B$178.48M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Airlines Group Inc

American Airlines (AAL) trades at $17.20, down 4.02% amid sector rotation. The stock shows a bullish technical signal with strong moving average alignment, though RSI levels are mixed. Fundamentally, revenue grew to $54.63B in 2025, but net income fell sharply to $111M, reflecting margin pressure. Recent news highlights airline sector volatility, with fuel cost declines offering relief but broader market sentiment weighing on travel stocks.

Outlook remains cautious; analyst consensus is split with a $19.96 price target suggesting modest upside. Key risks include volatile fuel prices, competitive pressures, and high debt levels. Earnings consistency is critical for sustained recovery, with Q2 2026 results pivotal for confirming operational improvements.

Heron Therapeutics Inc

HRTX trades at $0.4339, down 1.03% today, with neutral technical signals and mixed earnings performance. The company reported a Q1 2026 loss of $0.04 per share, missing estimates, but maintains a strong gross margin of 71.12% and a low P/S ratio of 0.47. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite quarterly pressures.

Outlook remains speculative given persistent net losses and negative cash flow from operations, though analyst consensus is overwhelmingly bullish with 94.74% buy ratings. Key risks include execution challenges and competitive threats in the biotechnology sector, while potential upside hinges on achieving profitability and successful product commercialization.

Returns comparison

Trailing returns across standard periods

About American Airlines Group Inc

American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.

Read more on AAL

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX